iTeos Therapeutics, Inc.
ITOS
$7.19
-$0.33-4.39%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | 35.00M | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | 35.00M | -- | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | -- | 35.00M | -- | 0.00 |
| SG&A Expenses | 11.81M | 12.11M | 12.46M | 12.70M | 12.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.48M | 48.63M | 48.27M | 46.43M | 37.77M |
| Operating Income | -48.48M | -48.63M | -13.27M | -46.43M | -37.77M |
| Income Before Tax | -36.36M | -43.12M | -4.87M | -36.00M | -28.19M |
| Income Tax Expenses | 7.36M | 2.24M | 2.26M | 2.21M | 2.36M |
| Earnings from Continuing Operations | -43.71M | -45.36M | -7.13M | -38.22M | -30.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.71M | -45.36M | -7.13M | -38.22M | -30.55M |
| EBIT | -48.48M | -48.63M | -13.27M | -46.43M | -37.77M |
| EBITDA | -48.16M | -48.32M | -12.96M | -46.13M | -37.54M |
| EPS Basic | -1.01 | -1.05 | -0.18 | -1.07 | -0.85 |
| Normalized Basic EPS | -0.53 | -0.62 | -0.08 | -0.63 | -0.49 |
| EPS Diluted | -1.01 | -1.05 | -0.18 | -1.07 | -0.85 |
| Normalized Diluted EPS | -0.53 | -0.62 | -0.08 | -0.63 | -0.49 |
| Average Basic Shares Outstanding | 43.18M | 43.14M | 39.70M | 35.84M | 35.79M |
| Average Diluted Shares Outstanding | 43.18M | 43.14M | 39.70M | 35.84M | 35.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
